Press Release Details

View all news

Elanco Announces Full Exercise of Additional Stock, Sets Date for Q3 Earnings

September 24, 2018
  • Elanco announces the underwriters of its recent initial public offering have exercised in full their over-allotment option purchase an additional 9.435 million shares
  • Elanco sets third quarter earnings call for Nov. 6, its first as an independent company
  • Elanco to ring the New York Stock Exchange Opening Bell® in celebration of its recent listing

GREENFIELD, Ind.--(BUSINESS WIRE)-- Elanco Animal Health Incorporated (NYSE:ELAN) announced the underwriters of its initial public offering (IPO) have fully exercised their option to purchase an additional 9.435 million shares at the initial public offering price of $24.00 per share, less underwriting discounts, bringing the total IPO size to 72.335 million shares.

Elanco’s shares began trading on the New York Stock Exchange (NYSE) on Sept. 20 under the ticker symbol “ELAN.” In celebration, Elanco is scheduled to ring the Opening Bell at NYSE today, Monday, Sept. 24.

“This marks an exciting new chapter for Elanco as we start our journey as an independently operated, publicly traded company,” said Jeff Simmons, president and chief executive officer of Elanco.

In addition, Elanco announced it will report its financial results for the third quarter of 2018 on Tuesday, Nov. 6, 2018. This marks Elanco’s first financial report as an independent company. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's financial performance.

The conference call will begin at 8 a.m. eastern time. Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Elanco's website at . A replay will also be available on the website following the conference call.

The NYSE will live stream the Opening Bell ceremony on it’s website at, beginning at 9:26 am Eastern Time on Monday, Sept. 24. A video of the bell ringing will also be archived on the same page.

A registration statement relating to these securities was filed with, and declared effective by, the U.S. Securities and Exchange Commission (SEC). This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Elanco Animal Health

Founded in 1954, Elanco provides comprehensive products and knowledge services to improve animal health and food-animal production in more than 90 countries around the world. We value innovation, both in scientific research and daily operations, and strive to cultivate a collaborative work environment for more than 5,800 employees worldwide. Together with our customers, we are committed to raising awareness about global food security, and celebrating and supporting the human-animal bond. Our worldwide headquarters and research facilities are located in Greenfield, Indiana.

This press release contains forward-looking statements that are based on management's current expectations, but actual results may differ materially due to various factors. These statements relate to the offering. There are significant risks and uncertainties relating to the offering. Important factors that could cause actual results to differ materially from management’s expectations include, without limitation: the satisfaction of customary closing conditions relating to the IPO; capital market risks; and the impact of general economic or industry conditions. There can be no guarantees that Elanco will achieve the anticipated benefits of the IPO. Elanco’s ability to achieve the anticipated benefits of the IPO may be materially affected by such factors as changes to the business, results of operation or financial condition of Elanco, changes in the animal health or pharmaceutical industries, adverse market or macroeconomic conditions and other factors outside Elanco's control. For additional information about the factors that affect Elanco's business, please see its filings with the SEC. Elanco undertakes no duty to update forward-looking statements, except as may be required by law.

Elanco Animal Health Incorporated
Colleen Parr Dekker, 317-989-7011
Jim Greffet, 317-383-9935

Source: Elanco Animal Health Incorporated

Categories: Press Releases
View all news